{"documentId":"1I8EvidenceDossierIndexMaster_yzA987BCdEfGhIjKlMno","title":"Evidence Dossier Index — Global Master","revisionId":"rev-1I8EvidenceD","body":{"content":[{"sectionBreak":{"sectionStyle":{"columnSeparatorStyle":"NONE","contentDirection":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":61,"textRun":{"content":"Evidence Dossier Index — Global Master (Veltarix / Zenvara)\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"TITLE","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":195,"textRun":{"content":"Maintained by Global Value & Access. Updated on every evidence asset change. Distribution: HTA leads (UK, DACH, France, Canada, EU JCA), HEOR Director, Clinical Development, Regulatory Affairs.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":10,"textRun":{"content":"Overview\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":402,"textRun":{"content":"The master index catalogs all evidence assets developed for Veltarix (Zenvara) global HTA and reimbursement submissions. Current count: 47 distinct evidence assets across clinical, economic, patient-reported outcome, real-world evidence, and budget impact categories. The index maps each asset to the HTA body submission requirement(s) it supports, the current asset status, and the responsible team.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":20,"textRun":{"content":"Counts by HTA body\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":101,"textRun":{"content":"NICE (UK): 12 evidence assets required, 10 complete, 2 in progress. Submission deadline 2026-09-01.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":137,"textRun":{"content":"G-BA (Germany): 11 evidence assets required (per AMNOG Module 1-5 structure), 8 complete, 3 in progress. Submission required at launch.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":126,"textRun":{"content":"HAS (France): 9 evidence assets required, 7 complete, 2 in progress. Submission to Commission de la Transparence in Q1 2027.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":166,"textRun":{"content":"CADTH/CDA-AMC (Canada): 8 evidence assets required, 6 complete, 2 in progress. Pre-submission Information Requirements Form due 120 days before complete submission.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":162,"textRun":{"content":"EU JCA (Joint Clinical Assessment): 7 evidence assets required, 3 complete, 4 in progress. JCA scoping in progress; 9 member states have submitted PICOs so far.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":37,"textRun":{"content":"Clinical evidence assets (12 total)\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":167,"textRun":{"content":"CL-001 ZENITH-1 Phase 3 primary publication (NEJM, March 2025). Status: published. Supports NICE Module B, G-BA Module 4, HAS clinical, CADTH clinical, JCA clinical.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":112,"textRun":{"content":"CL-002 ZENITH-1 long-term follow-up data (24-month update, ESMO 2025). Status: published. Same uses as CL-001.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":156,"textRun":{"content":"CL-003 ZENITH-1 4-year OS update (manuscript in preparation, target submission ASCO 2026 abstract). Status: complete, abstract under embargo until June 2.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":130,"textRun":{"content":"CL-004 ZENITH-1 subgroup analysis — PD-L1 TPS 50-79% vs 80%+. Status: complete. Supports NICE subgroup gap (gap 3 in NICE plan).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":96,"textRun":{"content":"CL-005 ZENITH-1 subgroup analysis — age, sex, race, ECOG performance status. Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":70,"textRun":{"content":"CL-006 ZENITH-1 safety extension data — 48 months. Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":118,"textRun":{"content":"CL-007 ITC vs platinum doublet (NMA report v3). Status: complete. Supports NICE comparator gap (gap 2 in NICE plan).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":87,"textRun":{"content":"CL-008 ITC vs atezolizumab (NMA report v2). Status: complete. Used in JCA submission.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":85,"textRun":{"content":"CL-009 ITC vs cemiplimab (NMA report v2). Status: complete. Used in JCA submission.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":212,"textRun":{"content":"CL-010 Real-world effectiveness — ZEN-RWD registry interim analysis. Status: in progress, target Q3 2026. Critical for closing NICE gap 1 (long-term durability) and G-BA evidence requirement on real-world data.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":113,"textRun":{"content":"CL-011 Cross-trial outcomes synthesis (Veltarix vs all comparators, Bucher and Bayesian NMA). Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":122,"textRun":{"content":"CL-012 Indication expansion preparation — IMpact-2 (2L NSCLC, PD-L1 1-49%). Status: enrolling. Readout targeted Q4 2026.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":37,"textRun":{"content":"Economic evidence assets (11 total)\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":176,"textRun":{"content":"EC-001 Cost-effectiveness model v6 (master). Partitioned-survival model with 4 states (PF, PD, AE, dead). Status: complete. Supports NICE Module C, G-BA Module 3, HAS, CADTH.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":105,"textRun":{"content":"EC-002 UK-specific cost-effectiveness model (NHS perspective, PSSRU 2025 unit costs). Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":108,"textRun":{"content":"EC-003 Germany-specific cost-effectiveness model (GKV perspective, EBM 2025 unit costs). Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":125,"textRun":{"content":"EC-004 France-specific cost-effectiveness model (Assurance Maladie perspective, ATIH 2025 unit costs). Status: in progress.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":106,"textRun":{"content":"EC-005 Canada-specific cost-effectiveness model (provincial drug plan perspective). Status: in progress.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":74,"textRun":{"content":"EC-006 5-year budget impact analysis — UK NHS England. Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":67,"textRun":{"content":"EC-007 5-year budget impact analysis — Germany. Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":69,"textRun":{"content":"EC-008 5-year budget impact analysis — France. Status: in progress.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":90,"textRun":{"content":"EC-009 5-year budget impact analysis — Canada (national + provincial). Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":75,"textRun":{"content":"EC-010 US Cost-effectiveness modeling for AMCP dossier. Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":79,"textRun":{"content":"EC-011 US Budget impact modeling for AMCP dossier (BIM v4). Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":37,"textRun":{"content":"Patient-reported outcomes (7 total)\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":67,"textRun":{"content":"PRO-001 ZENITH-1 EQ-5D-5L data — pivotal trial. Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":72,"textRun":{"content":"PRO-002 ZENITH-1 EORTC QLQ-C30 data — pivotal trial. Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":90,"textRun":{"content":"PRO-003 ZENITH-1 EORTC QLQ-LC13 data (NSCLC-specific) — pivotal trial. Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":96,"textRun":{"content":"PRO-004 ZENITH-1 Functional Assessment of Cancer Therapy-Lung (FACT-L) data. Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":73,"textRun":{"content":"PRO-005 Real-world PRO data from ZEN-RWD registry. Status: in progress.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":74,"textRun":{"content":"PRO-006 Utility valuation set — UK general population. Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":83,"textRun":{"content":"PRO-007 Patient organization submissions (NICE). Status: pending, due 2026-08-15.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":31,"textRun":{"content":"Real-world evidence (5 total)\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":63,"textRun":{"content":"RWE-001 ZEN-RWD registry baseline analysis. Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":106,"textRun":{"content":"RWE-002 ZEN-RWD registry interim analysis (real-world OS, PFS, treatment patterns). Status: in progress.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":78,"textRun":{"content":"RWE-003 Optum claims cohort analysis (n=12,400) — published JMCP March 2026.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":87,"textRun":{"content":"RWE-004 Flatiron/IBM MarketScan cohort analysis (Phase 1, n=4,800). Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":112,"textRun":{"content":"RWE-005 European RWE — Italian SIO registry, French AMIROS network, German DGHO registry. Status: in progress.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":40,"textRun":{"content":"Safety and pharmacovigilance (5 total)\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":61,"textRun":{"content":"PV-001 Risk Management Plan (EMA-format). Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":94,"textRun":{"content":"PV-002 Periodic Safety Update Report — first PBRER (post-marketing). Status: in preparation.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":68,"textRun":{"content":"PV-003 Phase 4 PMR safety surveillance protocol. Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":65,"textRun":{"content":"PV-004 Drug-drug interaction studies summary. Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":87,"textRun":{"content":"PV-005 Special populations safety data (renal, hepatic, geriatric). Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":35,"textRun":{"content":"Other supporting assets (7 total)\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":66,"textRun":{"content":"OTH-001 Patient advocacy engagement materials. Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":75,"textRun":{"content":"OTH-002 Clinician advisory board synthesis (KOL views). Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":90,"textRun":{"content":"OTH-003 Health-economic systematic literature review (UK perspective). Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":64,"textRun":{"content":"OTH-004 NICE scoping document (final scope). Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":87,"textRun":{"content":"OTH-005 G-BA Module 3 disease description and prevalence estimates. Status: complete.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":68,"textRun":{"content":"OTH-006 HAS therapeutic strategy positioning. Status: in progress.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":61,"textRun":{"content":"OTH-007 CADTH patient input templates. Status: in progress.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":17,"textRun":{"content":"Version control\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":252,"textRun":{"content":"Master model is held in the global value & access SharePoint at /Veltarix/Evidence/v6/. Each model version (EC-001 through EC-005) is versioned by date and lead analyst initials. Major version increments (v6 → v7) require sign-off from HEOR Director.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":238,"textRun":{"content":"Submission packages are assembled per body in /Veltarix/Submissions/<body>/ at submission time. Each submission package includes the dossier, the supporting evidence assets, the model files, and the responses to body-specific questions.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":18,"textRun":{"content":"Cross-references\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":150,"textRun":{"content":"NICE STA Submission Plan (1H3…), HTA Evidence Gap Report Q2 2026 (1J4…), 2024 G-BA Dossier Lessons Learned (1K7…), HEOR cost-effectiveness model v6.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}}]},"documentStyle":{"pageNumberStart":1,"marginTop":{"magnitude":72,"unit":"PT"},"marginBottom":{"magnitude":72,"unit":"PT"},"marginLeft":{"magnitude":72,"unit":"PT"},"marginRight":{"magnitude":72,"unit":"PT"},"pageSize":{"height":{"magnitude":792,"unit":"PT"},"width":{"magnitude":612,"unit":"PT"}}},"namedStyles":{"styles":[{"namedStyleType":"NORMAL_TEXT","textStyle":{"fontSize":{"magnitude":11,"unit":"PT"}}},{"namedStyleType":"TITLE","textStyle":{"fontSize":{"magnitude":26,"unit":"PT"},"bold":true}},{"namedStyleType":"HEADING_1","textStyle":{"fontSize":{"magnitude":20,"unit":"PT"},"bold":true}},{"namedStyleType":"HEADING_2","textStyle":{"fontSize":{"magnitude":16,"unit":"PT"},"bold":true}}]},"lists":{},"inlineObjects":{},"headers":{},"footers":{},"footnotes":{},"suggestionsViewMode":"DEFAULT_FOR_CURRENT_ACCESS"}